EU regulators quiz Novo Nordisk, Catalent rivals on $16.5 bln deal
Portfolio Pulse from
EU antitrust regulators are seeking feedback from pharmaceutical rivals and customers regarding Novo Holdings' proposed $16.5 billion acquisition of Catalent. The inquiry focuses on four business areas.
November 13, 2024 | 6:00 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Catalent is involved in a $16.5 billion acquisition by Novo Holdings, which is under scrutiny by EU regulators. Feedback is being sought from industry rivals.
The EU's inquiry into the acquisition could delay or alter the terms of the deal, impacting Catalent's stock. However, the outcome is uncertain, leading to a neutral short-term impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100